Abstract:Short major histocompatibility complex (MHC) class I (MHC-I)-restricted peptides contain the minimal biochemical information to induce antigen (Ag)-specific CD8+ cytotoxic T cell responses but are generally ineffective in doing so. To address this, we developed a cobalt–porphyrin (CoPoP) liposome vaccine adjuvant system that induces rapid particleization of conventional, short synthetic MHC-I epitopes, leading to strong cellular immune responses at nanogram dosing. Along with CoPoP (to induce particle formation of peptides), synthetic monophosphoryl lipid A (PHAD) and QS-21 immunostimulatory molecules were included in the liposome bilayer to generate the "CPQ" adjuvant system. In mice, immunization with a short MHC-I-restricted peptide, derived from glycoprotein 70 (gp70), admixed with CPQ safely generated functional, Ag-specific CD8+ T cells, resulting in the rejection of multiple tumor cell lines, with durable immunity. When cobalt was omitted, the otherwise identical peptide and adjuvant components did not result in peptide binding and were incapable of inducing immune responses, demonstrating the importance of stable particle formation. Immunization with the liposomal vaccine was well-tolerated and could control local and metastatic disease in a therapeutic setting. Mechanistic studies showed that particle-based peptides were better taken up by antigen-presenting cells, where they were putatively released within endosomes and phagosomes for display on MHC-I surfaces. On the basis of the potency of the approach, the platform was demonstrated as a tool for in vivo epitope screening of peptide microlibraries comprising a hundred peptides.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acsnano.0c07680?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acsnano.0c07680</a>.Supporting methods; figures showing synthesis schemes, 1H and 13C NMR and mass spectra, HPLC traces, cryo-electron micrographs, peptide bindings to liposomes, gating results, CPQ/A5 vaccination effects, impacts of PHAD, QS-21 and antigens, optional solubility tag effects, QS-21 and antigen dosage effects, liposomes draining, vaccine injection effects at multiple sites, macrophage uptake, PoP lipids coated on silica beads, liposome/peptide complexes, A5 with 2 his-tag released, fluorescence integrity, various length impacts of A5, QS-21 and peptide dose effects, CPQ as platform, details of peptide binding, cytotoxicities, Rragc385 DNA sequencing, and antitumor efficacy; tables listing 1H shifts and assignments, ICP analysis, representative UV–vis absorptions, polydispersities and ζ potentials, A5 peptides, and properties of A5 related and synthetic peptides (<a class="ext-link" href="/doi/suppl/10.1021/acsnano.0c07680/suppl_file/nn0c07680_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

The Pitx2 protein in mouse development

Ultrasound Improved Immune Adjuvant Delivery to Induce DC Maturation and T Cell Activation.

Immune Adjuvant Targeting Micelles Allow Efficient Dendritic Cell Migration to Lymph Nodes for Enhanced Cellular Immunity.

Induction of Cytotoxic T-Lymphocyte Responses Upon Subcutaneous Administration of a Subunit Vaccine Adjuvanted With an Emulsion Containing the Toll-Like Receptor 3 Ligand Poly(I:C)

Regulating tumor microenvironments by a lymph node-targeting adjuvant via tumor-specific CTL-derived IFNγ

Cationic nanoparticles enhance T cell tumor infiltration and antitumor immune responses to a melanoma vaccine

Efficacy of LCMV-based cancer immunotherapies is unleashed by intratumoral injections of polyI:C

HCA587/MAGE-C2 protein formulated with CFA and CpG elicits potent immune responses and antitumor effects in mice

Polymersomal Poly(I:C) Self‐Magnifies Antitumor Immunity by Inducing Immunogenic Cell Death and Systemic Immune Activation

Enhanced Immune Response Against the Thomsen-Friedenreich Tumor Antigen Using a Bivalent Entirely Carbohydrate Conjugate

Improved cytotoxic T-lymphocyte immune responses to a tumor antigen by vaccines co-expressing the SLAM-associated adaptor EAT-2

Induction of HCA587-Specific Antitumor Immunity with HCA587 Protein Formulated with CpG and ISCOM in Mice

An 15N NMR study of the protonation of two di-(alpha-pyridyl) compounds in solutions and the solid state.

Brief Communication: Combination of an MIP3α-Antigen Fusion Therapeutic DNA Vaccine With Treatments of IFNα and 5-Aza-2'Deoxycytidine Enhances Activated Effector CD8+ T Cells Expressing CD11c in the B16F10 Melanoma Model

Enhanced Vaccine Immunogenicity Enabled by Targeted Cytosolic Delivery of Tumor Antigens into Dendritic Cells

Fully Synthetic Invariant NKT Cell-Dependent Self-Adjuvanting Antitumor Vaccines Eliciting Potent Immune Response in Mice.

An all-in-one adjuvanted therapeutic cancer vaccine targeting dendritic cell cytosol induces long-lived tumor suppression through NLRC4 inflammasome activation.

Co-administration of Carcinoembryonic Antigen and Hiv Tat Fusion Protein with Cpg-oligodeoxynucleotide Induces Potent Antitumor Immunity Although Dendritic Cells (dc) Have Been Well Demonstrated as a Strong Cellular Adjuvant for a Tumor Vaccine, There Are Several Limitations for Clinical Application

A Potent Cancer Vaccine Adjuvant System for Particleization of Short, Synthetic CD8 + T Cell Epitopes

Cysteine-binding adjuvant enhances survival and promotes immune function in a murine model of acute myeloid leukemia

Maximizing TLR9 Activation in Cancer Immunotherapy with Dual-Adjuvanted Spherical Nucleic Acids